Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10238797 | 0.81 | DRD2 (0.40) | CA1CA2 | |
| SCHEMBL2077243 | 0.80 | HTR2A (0.56) | CA1CA2HTR2AHTR2CHTR2B | |
| SCHEMBL30001510 | 0.79 | CYP11B1 (0.34) | HTTKMT2A | |
| SCHEMBL24327696 | 0.79 | HTT (0.35) | HTTKMT2A | |
| SCHEMBL17942174 | 0.79 | CYP11B1 (0.34) | HTTKMT2A | |
| SCHEMBL31362556 | 0.75 | MAOA (0.40) | HTR2AHTR2CHTR2BHSD17B10SMN1; SMN2 | |
| SCHEMBL24336051 | 0.75 | CA1 (0.39) | CA1CA2HTR2AHTR2CHTR2B | |
| SCHEMBL31362442 | 0.74 | MAOA (0.41) | CHRNB2CHRNA4HSD17B10 | |
| SCHEMBL15309331 | 0.73 | UGT2B17 (0.38) | — | |
| SCHEMBL15309244 | 0.73 | CYP11B1 (0.35) | CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180079743-A1 | FACTOR XIa INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180079743-A1 | FACTOR XIa INHIBITORS | F11, F2, TFPI | CA1 2317/4885CA2 1986/4885HTR2A 4336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.